Re: 'Real world clinical outcome of cefiderocol for treatment of multidrug-resistant nonfermenting gram-negative bacilli infections' by Hoellinger et al.
作者信息
Larcher Romaric, Laffont-Lozes Paul, Loubet Paul, Laureillard Didier, Naciri Tayma, Sotto Albert
机构信息
PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, France and Department of Infectious and Tropical Diseases, Nîmes University Hospital, France.
Department of Infectious and Tropical Diseases and Department of Pharmacy, Nîmes University Hospital, France.
出版信息
Clin Microbiol Infect. 2023 Jun;29(6):808-811. doi: 10.1016/j.cmi.2023.01.022. Epub 2023 Feb 3.
PMID:36739087
Abstract
摘要
相似文献
1
Re: 'Real world clinical outcome of cefiderocol for treatment of multidrug-resistant nonfermenting gram-negative bacilli infections' by Hoellinger et al.回复：霍林格等人所著的《头孢地尔治疗多重耐药非发酵革兰氏阴性杆菌感染的真实世界临床结局》
Clin Microbiol Infect. 2023 Jun;29(6):808-811. doi: 10.1016/j.cmi.2023.01.022. Epub 2023 Feb 3.
2
Re: real world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting gram-negative bacilli infections: author's response.关于：头孢地尔治疗多重耐药非发酵革兰氏阴性杆菌感染的真实世界临床结局：作者回复
Clin Microbiol Infect. 2023 Jun;29(6):812-813. doi: 10.1016/j.cmi.2023.02.019. Epub 2023 Mar 5.
3
Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series.头孢地尔治疗多重耐药非发酵革兰阴性杆菌感染的真实世界临床结局：病例系列
Clin Microbiol Infect. 2023 Mar;29(3):393-395. doi: 10.1016/j.cmi.2022.11.005. Epub 2022 Nov 18.
4
Cefiderocol: Clinical application and emergence of resistance.头孢地尔：临床应用与耐药性的出现
Drug Resist Updat. 2024 Jan;72:101034. doi: 10.1016/j.drup.2023.101034. Epub 2023 Dec 18.
5
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
6
Cefiderocol: A Siderophore Cephalosporin.头孢地尔：一种铁载体头孢菌素。
Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10.
7
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.多药耐药非发酵革兰阴性杆菌感染的新治疗方法。
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):51-53. doi: 10.37201/req/s03.12.2022. Epub 2022 Oct 24.
8
Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series.头孢地尔在儿童多重耐药革兰阴性菌感染或定植管理中的应用：一项回顾性单中心病例系列研究。
Pediatr Infect Dis J. 2024 Aug 1;43(8):772-776. doi: 10.1097/INF.0000000000004347. Epub 2024 Apr 2.
9
Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.非发酵革兰氏阴性菌中的耐药性：最大程度的多重耐药。
Am J Med. 2006 Jun;119(6 Suppl 1):S29-36; discussion S62-70. doi: 10.1016/j.amjmed.2006.03.014.
10
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.1991年至2003年台湾某大学医院引起医院感染的革兰氏阴性菌中抗菌药物使用与抗菌药物耐药性之间的关系。
Int J Antimicrob Agents. 2005 Dec;26(6):463-72. doi: 10.1016/j.ijantimicag.2005.08.016. Epub 2005 Nov 8.
引用本文的文献
1
Adaptive resistance to cefiderocol in carbapenem-resistant (CRAB): Microbiological and clinical issues.耐碳青霉烯类鲍曼不动杆菌（CRAB）对头孢地尔的适应性耐药：微生物学和临床问题
Heliyon. 2024 Apr 26;10(9):e30365. doi: 10.1016/j.heliyon.2024.e30365. eCollection 2024 May 15.
Zotero 插件